We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+15.28%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
-$394M
Cap. Flow
-$894M
Cap. Flow %
-41.57%
Top 10 Hldgs %
42.88%
Holding
116
New
14
Increased
12
Reduced
29
Closed
26

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$48.4M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$46.1M
3
TSRO
TESARO, Inc.
TSRO
+$22.6M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$21.3M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
XNPT
XENOPORT, INC.
XNPT
+$81.5M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$49.8M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$35.4M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.12%
2 Financials 3.34%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
76
DELISTED
Molecular Templates, Inc.
MTEM
$1.49M 0.07%
13,346
-2,310
-15% -$317K
TEVA icon
77
Teva Pharmaceuticals
TEVA
$37.3B
$1.38M 0.06%
+30,000
New +$1.57M
REGN icon
78
Regeneron Pharmaceuticals
REGN
$70.9B
$1.33M 0.06%
+3,300
New +$1.32M
PRTK
79
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.3M 0.06%
100,000
– –
BMRN icon
80
BioMarin Pharmaceuticals
BMRN
$11.5B
$1.28M 0.06%
+13,800
New +$1.3M
STRM
81
DELISTED
Streamline Health Solutions
STRM
$1.22M 0.06%
44,198
– –
CLVS
82
DELISTED
Clovis Oncology, Inc.
CLVS
$288K 0.01%
8,000
-161,506
-95% -$3.47M
ALDX icon
83
Aldeyra Therapeutics
ALDX
$102M
– –
-267,764
Closed -$1.52M
ALNY icon
84
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-336,000
Closed -$18.6M
ARCT icon
85
Arcturus Therapeutics
ARCT
$172M
– –
-152,845
Closed -$4.8M
ATEC icon
86
Alphatec Holdings
ATEC
$1.31B
– –
-415,228
Closed -$1.75M
CDNA icon
87
CareDx
CDNA
$2.05B
– –
-51,204
Closed -$221K
CI icon
88
Cigna
CI
$74.5B
– –
-171,000
Closed -$21.9M
INCY icon
89
Incyte
INCY
$23.4B
– –
-91,000
Closed -$7.28M
LRMR icon
90
Larimar Therapeutics
LRMR
$384M
– –
-254,634
Closed -$18.3M
MOH icon
91
Molina Healthcare
MOH
$11.7B
– –
-436,000
Closed -$21.8M
PACB icon
92
Pacific Biosciences
PACB
$447M
– –
-63,072
Closed -$444K
PCRX icon
93
Pacira BioSciences
PCRX
$1.01B
– –
-50,000
Closed -$1.69M
RGNX icon
94
Regenxbio
RGNX
$511M
– –
-1,169,042
Closed -$9.35M
RIGL icon
95
Rigel Pharmaceuticals
RIGL
$750M
– –
-233,137
Closed -$5.2M
TCON
96
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-338
Closed -$296K
LCI
97
DELISTED
Lannett Company, Inc.
LCI
– –
-223,898
Closed -$21.3M
ENDP
98
DELISTED
Endo International plc
ENDP
– –
-30,000
Closed -$468K
EGLT
99
DELISTED
Egalet Corporation
EGLT
– –
-162,288
Closed -$805K
COTV
100
DELISTED
Cotiviti Holdings, Inc.
COTV
– –
-900,079
Closed -$19M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2016 Portfolio in Review

As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XENOPORT, INC., an estimated $81.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $56M.

  • Deerfield Management's largest Q3 2016 buy was NEVRO CORP.: 536,355 shares worth $56M.
  • Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q3 2016, an estimated $46.1M increase.
  • Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $143M.
  • Deerfield Management fully exited XENOPORT, INC. in Q3 2016, selling an estimated $81.5M.
  • Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
  • Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
  • Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.